V

Voyager Therapeutics
D

VYGR

4.22500
USD
-0.04
(-0.94%)
مغلق
حجم التداول
3,060
الربح لكل سهم
-1
العائد الربحي
-
P/E
6
حجم السوق
230,793,101
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALKS
    -0.240
    (-0.68%)
    35.260 USD
    A
    ARCT
    0.846
    (5.00%)
    17.770 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CLLS
    -0.02000
    (-1.30%)
    1.52000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    المزيد
الأخبار
المقالات

العنوان: Voyager Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.